Last reviewed · How we verify
NCT04512534: Sincerely20
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Recruiting now
Phase 2
Last updated 2 April 2026
What this trial tests
Phase 2 trial testing PD-1 antibody+ HDAC inhibitor in Peripheral T-cell Lymphoma in 51 participants. Currently enrolling.
Timeline
13 November 2020
Primary endpoint
1 December 2026
1 December 2026
31 December 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 13 November 2020 |
| Primary completion | 1 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- PD-1 antibody+ HDAC inhibitor — full drug profile →
Conditions studied
- Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →
Sponsor
Fudan University
Who can join
Adults 18 to 75, any sex, with Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy.
Tan Y, Wang M, Zhang Y, Ge S, et al · · 2021 · cited 96× · PMID 34178692 · DOI 10.3389/fonc.2021.693517 -
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6 -
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914 -
Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y, Li X, Luan Y, Luo J, et al · · 2024 · cited 34× · PMID 38178117 · DOI 10.1186/s12943-023-01904-w -
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities.
Dai M, Liu M, Yang H, Küçük C, et al · · 2022 · cited 30× · PMID 36384676 · DOI 10.1186/s40164-022-00356-0 -
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
Xu Y, Li P, Liu Y, Xin D, et al · · 2022 · cited 29× · PMID 35642676 · DOI 10.1002/cac2.12313 -
Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.
Tang Y, Cui G, Liu H, Han Y, et al · · 2024 · cited 28× · PMID 38715348 · DOI 10.1002/cac2.12546 -
Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors.
Liang Y, Wang L, Ma P, Ju D, et al · · 2023 · cited 21× · PMID 38077327 · DOI 10.3389/fimmu.2023.1308264
Verify or expand the search:
- PubMed search for NCT04512534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral T-cell Lymphoma
Currently open trials in the same condition.
- NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT06914037 — A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT07072221 — Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients · NA · recruiting
- NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL · Phase 1, PHASE2 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04512534 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04512534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing